RTTNews | Jun 21, 2021 09:17AM EDT

09:17 Monday, June 21, 2021 (RTTNews.com) - Immutep Limited (IMMP, IMM.AX) said Monday that it will commence a new phase I trial, called INSIGHT-003, to evaluate the combination of lead product candidate eftilagimod alpha or "efti" or "IMP321" in conjunction with an existing approved standard of care therapy consisting of a chemotherapy agent and an anti-PD-1 therapy.

Maximum 20 patients with various solid tumours will be recruited to participate in the trial. Patients will receive 30 mg doses of efti every two weeks for 24 weeks in conjunction with standard of care chemotherapy plus anti-PD-1 therapy.

The company noted that patients will enter a maintenance phase and receive either efti alone or in double or continued triple combination with anti-PD-1 therapy. The trial will assess the safety, tolerability and initial efficacy of the combination.

All regulatory and ethical approvals have been received, enabling recruitment to commence.

The first patient is expected to be enrolled in third-quarter of calendar year 2021, with first interim results expected in 2022.

Read the original article on RTTNews ( https://www.rttnews.com/3203774/immutep-to-evaluate-efti-in-phase-i-study-with-chemotherapy-and-anti-pd-1-therapy.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved